Here are the DEF 14A proxy statements from Aprea Therapeutics, Inc. (APRE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow APRE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APRE filings page.
Aprea Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, a potential reverse stock split and executive pay matters. The June 16, 2026 meeting will be held online for holders of record as of April 21, 2026.
Stockholders will vote on electing three Class I directors to 2029, ratifying EisnerAmper LLP as auditor for 2026, approving a reverse stock split at a Board-selected ratio between 1-for-3 and 1-for-8 without reducing authorized shares, and two advisory “say on pay” items. A proposal also allows adjourning the meeting to seek more proxies if needed for the reverse split.